NEULAND LABORATORIES
|
NEULAND LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 127.45 | 49.74 | 62.85 | 12.63 | 12.82 |
| CEPS(Rs) | 168.59 | 87.97 | 93.78 | 37.02 | 32.97 |
| DPS(Rs) | 10.00 | 5.00 | 5.00 | 2.00 | 1.20 |
| Book NAV/Share(Rs) | 774.12 | 654.40 | 612.28 | 552.65 | 544.35 |
| Tax Rate(%) | 24.21 | 22.32 | 23.45 | 69.37 | 19.16 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 22.82 | 15.00 | 15.67 | 13.36 | 8.75 |
| EBIT Margin(%) | 19.21 | 10.06 | 13.15 | 9.77 | 5.40 |
| Pre Tax Margin(%) | 18.11 | 8.64 | 11.24 | 6.94 | 3.05 |
| PAT Margin (%) | 13.73 | 6.71 | 8.61 | 2.13 | 2.47 |
| Cash Profit Margin (%) | 18.16 | 11.87 | 12.84 | 6.23 | 6.34 |
| Performance Ratios | |||||
| ROA(%) | 11.04 | 4.71 | 6.31 | 1.37 | 1.49 |
| ROE(%) | 17.84 | 7.85 | 10.79 | 2.30 | 3.48 |
| ROCE(%) | 20.94 | 9.44 | 12.81 | 7.85 | 3.99 |
| Asset Turnover(x) | 0.80 | 0.70 | 0.73 | 0.65 | 0.61 |
| Sales/Fixed Asset(x) | 1.28 | 1.09 | 1.22 | 1.18 | 1.26 |
| Working Capital/Sales(x) | 3.70 | 4.37 | 5.17 | 4.84 | 5.27 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.78 | 0.91 | 0.82 | 0.85 | 0.79 |
| Receivable days | 91.33 | 86.74 | 79.40 | 84.68 | 97.96 |
| Inventory Days | 83.41 | 98.40 | 91.00 | 98.63 | 100.64 |
| Payable days | 110.05 | 116.52 | 111.44 | 112.92 | 121.57 |
| Valuation Parameters | |||||
| PER(x) | 14.12 | 20.64 | 33.22 | 22.43 | 52.62 |
| PCE(x) | 10.67 | 11.67 | 22.27 | 7.66 | 20.45 |
| Price/Book(x) | 2.32 | 1.57 | 3.41 | 0.51 | 1.24 |
| Yield(%) | 0.56 | 0.49 | 0.24 | 0.71 | 0.18 |
| EV/Net Sales(x) | 1.99 | 1.61 | 3.02 | 0.76 | 1.59 |
| EV/Core EBITDA(x) | 8.42 | 10.56 | 17.37 | 5.45 | 17.12 |
| EV/EBIT(x) | 10.36 | 15.97 | 22.96 | 7.74 | 29.41 |
| EV/CE(x) | 1.50 | 1.10 | 2.14 | 0.47 | 0.94 |
| M Cap / Sales | 1.94 | 1.38 | 2.86 | 0.48 | 1.30 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 25.25 | 1.51 | 22.84 | 14.38 | 26.44 |
| Core EBITDA Growth(%) | 94.61 | -11.18 | 54.02 | 70.98 | 12.55 |
| EBIT Growth(%) | 139.20 | -22.38 | 65.42 | 106.93 | 9.55 |
| PAT Growth(%) | 156.21 | -20.85 | 397.40 | -1.41 | 36.30 |
| EPS Growth(%) | 156.21 | -20.85 | 397.40 | -1.41 | -5.62 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.28 | 0.22 | 0.37 | 0.33 |
| Current Ratio(x) | 1.73 | 1.60 | 1.49 | 1.44 | 1.39 |
| Quick Ratio(x) | 1.10 | 0.87 | 0.82 | 0.83 | 0.80 |
| Interest Cover(x) | 17.51 | 7.09 | 6.89 | 3.45 | 2.30 |
| Total Debt/Mcap(x) | 0.05 | 0.18 | 0.06 | 0.71 | 0.27 |
Compare Financial Ratios of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹9,431.6 Cr | 5.7% | -7.9% | 288.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹365,311.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹108,623.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,134.3 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹97,408.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹92,794.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 5.7% |
-7.9% |
288.4% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
